Potassium Chloride

# Potassium chloride ## Overview - **Classification**: Electrolyte, mineral replacement - **Mechanism**: Essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and normal kidney function. Replenishes depleted potassium stores. ## Primary Indications 1. **Hypokalemia Treatment**: For patients with documented low serum potassium levels. 2. **Hypokalemia Prevention**: In patients at high risk of potassium depletion (e.g., diuretic therapy, GI fluid loss). 3. **Digitalis Toxicity**: As an adjunct in managing arrhythmias caused by hypokalemia-induced digitalis toxicity. ## Adult Dosing ### Standard Dosing **Hypokalemia Treatment (Mild-Moderate, Oral)** - **Dose**: **20-40 mEq** - **Frequency**: Once daily or in divided doses (e.g., twice daily) - **Route**: Oral (PO) - **Special Considerations**: Administer with food or after meals to minimize GI irritation. **Hypokalemia Treatment (Moderate-Severe or Symptomatic, Intravenous)** - **Dose**: **10-20 mEq** - **Frequency**: Infused over **1-2 hours**. May repeat as needed based on potassium levels. - **Route**: Intravenous (IV) - **Maximum Dose**: Peripheral IV **10 mEq/hr** (some sources up to **20 mEq/hr** in critical care). Central IV up to **20 mEq/hr** with continuous ECG monitoring. Total daily maximum typically **200 mEq**, up to **400 mEq** in severe cases. - **Special Considerations**: Always dilute IV potassium. Never administer IV push. Monitor ECG and serum potassium closely. **Hypokalemia Prevention (Oral)** - **Dose**: **10-20 mEq** - **Frequency**: Once daily or in divided doses - **Route**: Oral (PO) ### Dose Adjustments - **Renal Impairment**: Avoid or use with extreme caution in severe renal impairment (CrCl < 30 mL/min). Dose reduction often required. - **Contraindicated** in anuria or oliguria. - **Hepatic Impairment**: No specific dose adjustment recommended; primarily renally eliminated. - **Elderly Patients**: Start with lower doses due to potential age-related decline in renal function and increased risk of hyperkalemia. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **0.5-1 mEq/kg/dose** - **Frequency**: IV over **1-2 hours**. For prophylaxis: **1-2 mEq/kg/day** PO in 1-2 divided doses. - **Maximum**: **1 mEq/kg/hour** for IV infusion, not to exceed **10 mEq/hour**. - **Special Notes**: Always dilute IV potassium. Monitor serum potassium and ECG closely due to immature renal function. ### Infants (1-12 months) - **Dose**: Hypokalemia Treatment (IV): **0.5-1 mEq/kg/dose** IV. Hypokalemia Prevention/Mild Treatment (PO): **1-2 mEq/kg/day** in 1-2 divided doses. - **Frequency**: IV over **1-2 hours**. PO daily or twice daily. - **Maximum**: IV **1 mEq/kg/hour** (max **20 mEq/hour**). Total daily **3 mEq/kg/day** IV (max **40 mEq/day** PO). ### Children (1-12 years) - **Dose**: Hypokalemia Treatment (IV): **0.5-1 mEq/kg/dose** IV. Hypokalemia Prevention/Mild Treatment (PO): **1-2 mEq/kg/day** in 1-2 divided doses. - **Frequency**: IV over **1-2 hours**. PO daily or twice daily. - **Maximum**: IV **1 mEq/kg/hour** (max **20 mEq/hour**). Total daily **3 mEq/kg/day** IV (max **100 mEq/day** PO). ### Adolescents (13-18 years) - **Dose**: Generally follows adult dosing guidelines. - **Maximum**: Adult maximum doses apply (e.g., **20 mEq/hr** IV, total daily **200-400 mEq**). ## Safety Information ### Contraindications - **Absolute**: Hyperkalemia (serum K+ > 5.0 mEq/L) - **Absolute**: Severe renal impairment (anuria, oliguria) - **Absolute**: Untreated Addison's disease - **Absolute**: Acute dehydration - **Absolute**: Conditions predisposing to hyperkalemia (e.g., potassium-sparing diuretics) - **Relative**: GI obstruction, peptic ulcer disease (oral formulations) ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, diarrhea, abdominal discomfort (oral forms) - **Common (1-10%)**: Injection site pain/phlebitis (IV), flatulence - **Serious but Rare**: Hyperkalemia (potentially fatal cardiac arrhythmias), GI ulceration/perforation (oral, especially solid forms) ### Key Drug Interactions - **ACE inhibitors/ARBs**: Increased risk of hyperkalemia. Monitor serum potassium closely. - **Potassium-sparing diuretics**: Significantly increased risk of severe hyperkalemia. **Contraindicated** for concomitant use. - **NSAIDs**: May reduce renal potassium excretion, increasing hyperkalemia risk. Monitor potassium levels. - **Cyclosporine/Tacrolimus**: May cause hyperkalemia. Monitor potassium levels. ## Monitoring & Follow-up - **Before Treatment**: Baseline serum potassium, renal function (BUN, creatinine), ECG (if cardiac risk factors or IV administration planned). - **During Treatment**: Serum potassium (daily or more frequently with IV, then every 2-3 days with PO), renal function, ECG monitoring (continuously with rapid IV infusion). - **Clinical Signs**: Monitor for signs of hyperkalemia (muscle weakness, paresthesias, fatigue, cardiac arrhythmias) or hypokalemia (muscle cramps, weakness, fatigue, palpitations). ## Clinical Pearls - 💡 **Always dilute IV KCl**: Never administer undiluted or as an IV push; this can be fatal. - 💡 **Oral administration**: Advise patients to take oral potassium with food or after meals to minimize GI upset and potential for ulceration. - 💡 **IV Infusion Rate**: Slow infusion is critical for safety. Peripheral IV max **10 mEq/hr** (some exceptions in critical care up to 20 mEq/hr with close monitoring). - 💡 **Formulation Choice**: Liquid or effervescent tablets are generally preferred over wax-matrix or microencapsulated tablets due to lower risk of GI irritation/ulceration. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.